每经头条（nbdtoutiao）——"一针两千，童颜针年销3亿元"背后：多家关联方注册地"查无此人"，股民 追问"钱呢"！钱氏姐弟几乎"掏空"江苏吴中，公司即将退市 每经AI快讯，国药一致（SZ 000028，收盘价：24.61元）12月15日晚间发布公告称，公司第十届2025年 第九次董事会临时会议于2025年12月15日以通讯表决方式召开。会议审议了《关于召开2025年第三次临 时股东会的议案》等文件。 2025年1至6月份，国药一致的营业收入构成为：医药批发占比70.21%，医药零售占比29.28%，其他产 品占比0.51%。 截至发稿，国药一致市值为137亿元。 （记者 曾健辉） ...

Company Overview - Yingte Group (SZ 000411) announced the convening of its 10th Board of Directors meeting on November 5, 2025, via telecommunication to review the proposal for the reappointment of the financial report and internal control audit institution for the fiscal year 2025 [1] Financial Performance - For the first half of 2025, Yingte Group's revenue composition was as follows: pharmaceutical wholesale accounted for 89.1%, pharmaceutical retail accounted for 10.34%, and other industries accounted for 0.56% [1] Market Capitalization - As of the report, Yingte Group's market capitalization stood at 5.9 billion yuan [1]

Group 1 - The core point of the article is that Chongqing Pharmaceutical Holdings (SZ 000950) announced a board meeting to discuss the transfer of a 20% stake in Chongqing Huayi Holdings Financial Co., Ltd. and related transactions [1] - For the first half of 2025, the revenue composition of Chongqing Pharmaceutical Holdings was as follows: 94.81% from pharmaceutical wholesale, 4.73% from pharmaceutical retail, and 0.46% from other businesses [1] - As of the report date, the market capitalization of Chongqing Pharmaceutical Holdings was 9.2 billion yuan [1]

Group 1 - The core point of the article highlights that Zhongyao Holdings (SZ 000950) held its 18th meeting of the 9th board of directors on September 29, 2025, via telecommunication to discuss the proposal for the fourth extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Zhongyao Holdings reported that its revenue composition was 94.81% from pharmaceutical wholesale, 4.73% from pharmaceutical retail, and 0.46% from other businesses [1] - As of the report date, Zhongyao Holdings had a market capitalization of 8.8 billion yuan [1] Group 2 - The article also discusses the competitive landscape in the beverage industry, noting that after the launch of the Farmer Green Bottle, Yibao experienced a significant decline in market share, dropping nearly 5 percentage points [1]

Group 1 - Zhejiang Zhenyuan's stock price increased by 7.44% to 9.97 CNY per share, with a trading volume of 102 million CNY and a turnover rate of 3.82%, resulting in a total market capitalization of 3.33 billion CNY [1] - The company, established on April 2, 1993, and listed on April 10, 1997, is primarily engaged in pharmaceutical wholesale and retail, production and sales of traditional Chinese medicine pieces, and research and production of raw materials and formulations [1] - The revenue composition of Zhejiang Zhenyuan includes: retail business 45.55%, wholesale business 28.75%, industrial formulations 14.08%, industrial raw materials 7.94%, health services 2.88%, and others 0.80% [1] Group 2 - Baodao Yuanhang Mixed A Fund (007126) entered the top ten circulating shareholders of Zhejiang Zhenyuan, holding 1.2032 million shares, which is 0.43% of the circulating shares, with an estimated floating profit of approximately 830,200 CNY [2] - The fund was established on April 30, 2019, with a latest scale of 1.685 billion CNY, achieving a year-to-date return of 31.48% and a one-year return of 62.63% [2] - Since its inception, the fund has generated a return of 105.2%, with its performance ranking 2766 out of 8172 in the same category this year and 2218 out of 7980 over the past year [2] Group 3 - The fund manager of Baodao Yuanhang Mixed A is Yang Meng, who has been in the position for 7 years and 42 days, managing a total fund size of 12.691 billion CNY [3] - During Yang Meng's tenure, the best fund return was 172.23%, while the worst return was -27.34% [3]

Group 1 - The company announced a provision for asset impairment, which is expected to reduce the net profit attributable to shareholders by approximately 197 million yuan for the first half of 2025 [1][3] - The impairment provision will also correspondingly decrease the equity attributable to shareholders by about 197 million yuan [1][3] - The impairment provision of approximately 377 million yuan was made after an inspection and analysis of various assets within the consolidation scope [3] Group 2 - For the year 2024, the revenue composition of Zhongyao Holdings is as follows: 95.03% from pharmaceutical wholesale, 4.59% from pharmaceutical retail, and 0.38% from other businesses [1]

Group 1 - The company announced the appointment of Liu Wei as the vice general manager, following the nomination by the general manager and approval by the board's nomination committee [2] - For the year 2024, the revenue composition of the company is as follows: 95.03% from pharmaceutical wholesale, 4.59% from pharmaceutical retail, and 0.38% from other businesses [2]